natgillin/translations-raw huggingface dataset:
Stråleterapi: MTD for capecitabin alene ved anvendelse af det intermitterende regime er 3.000 mg/m2 pr. dag, hvorimod MTD er 2.000 mg/m2 pr. dag, når capecitabin kombineres med stråleterapi ved kolorektalkræft, enten ved anvendelse af en kontinuerlig behandling eller anvendt dagligt fra mandag til fredag under en seks ugers serie med stråleterapi.
Radiotherapy: the MTD of capecitabine alone using the intermittent regimen is 3000 mg/m2 per day, whereas, when combined with radiotherapy for rectal cancer, the MTD of capecitabine is 2000 mg/m2 per day using either a continuous schedule or given daily Monday through Friday during a 6-week course of radiotherapy.
Stråling
Energy (keV)
Stråling blev udført med megavolt-udstyr med én fraktionering dagligt (2 Gy pr. dag, 5 dage om ugen i 7 uger, dosis i alt
Radiation was delivered with megavoltage equipment using once daily fractionation (2 Gy per day, 5 days per week for 7 weeks, for a total dose of
Stråling blev udført med megavolt-udstyr, med en daglig fraktionering (2 Gy pr. dag, 5 dage om ugen i 7 uger, dosis i alt
Radiation was delivered with megavoltage equipment using once daily fractionation (2 Gy per day, 5 days per week for 7 weeks, for a total dose of
Stråling fra de udsendte beta-partikler fra 90Y sker i en radius på 5 mm rundt om isotopen.
Irradiation by the emitted beta particles from 90Y occurs in a radius of 5 mm around the isotope.
Strålingsdosis for forskellige organer efter indgivelse af et yttrium (90Y)-mærket lægemiddel er afhængig af det specifikke præparat, som radiomærkes.
The radiation dose received by the various organs following administration of a Yttrium (90Y)- labelled medicinal product will be dependent on the specific pharmaceutical being radiolabelled.
Strålingsdosis fra 18FDG-PET (Fluorodeoxyglucose – Positron Emission Tomography) er lavere end fra NeoSpect , med opnåelse af høj sensitivitet og specificitet.
The radiation dose from 18FDG-PET (Fluorodeoxyglucose – Positron Emission Tomography) is lower than that from NeoSpect, whilst still achieving high sensitivity and specificity.
Strålingsinduceret dermatitis og solforbrændinger kan dukke op igen under behandling med methotrexat (recall-reaktion).
Radiation induced dermatitis and sun-burn can reappear under methotrexate therapy recall-reaction).
Strålingspneumonitis (arvæv i de fineste bronkier samt alveolerne på grund af strålebehandling) kan opstå hos patienter, som også behandles med stråling enten før, under eller efter deres behandling med ALIMTA.
Radiation pneumonitis (scarring of the air sacs of the lung associated with radiation therapy) may occur in patients who are also treated with radiation either before, during or after their ALIMTA therapy.
Strålingspneumonitis (arvæv i de fineste bronkier samt alveolerne på grund af strålebehandling) kan opstå hos patienter, som også behandles med stråling enten før, under eller efter deres behandling med Pemetrexed Accord.
Radiation pneumonitis (scarring of the air sacs of the lung associated with radiation therapy) may occur in patients who are also treated with radiation either before, during or after their Pemetrexed Accord therapy.
Strålingspneumonitis (arvæv i de fineste bronkier samt alveolerne på grund af strålebehandling) kan opstå hos patienter, som også behandles med stråling enten før, under eller efter deres behandling med Pemetrexed Lilly.
Radiation pneumonitis (scarring of the air sacs of the lung associated with radiation therapy) may occur in patients who are also treated with radiation either before, during or after their Pemetrexed Lilly therapy.
Strålingspneumonitis (arvæv i de fineste bronkier samt alveolerne på grund af strålebehandling) kan opstå hos patienter, som også behandles med stråling enten før, under eller efter deres behandling med Pemetrexed medac
Radiation pneumonitis (scarring of the air sacs of the lung associated with radiation therapy) may occur in patients who are also treated with radiation either before, during or after their Pemetrexed medac therapy.
Strålingspneumonitis (arvæv i de fineste bronkier samt alveolerne på grund af strålebehandling) kan opstå hos patienter, som også behandles med stråling enten før, under eller efter deres behandling med Pemetrexed Sandoz.
Radiation pneumonitis (scarring of the air sacs of the lung associated with radiation therapy) may occur in patients who are also treated with radiation either before, during or after their Pemetrexed Sandoz therapy.
Strålingspneumonitis (arvæv i de fineste bronkier samt alveolerne på grund af strålebehandling) kan opstå hos patienter, som også behandles med stråling enten før, under eller efter deres behandling med pemetrexed.
Radiation pneumonitis (scarring of the air sacs of the lung associated with radiation therapy) may occur in patients who are also treated with radiation before, during or after their pemetrexed therapy
Strålingssikkerhed – håndtering af præparatet
Radiation safety – Product handling
Stræk
Stretch
Stræk eller klem sammen om injektionsstedet, så der dannes et fast underlag.
Stretch or pinch your injection site to create a firm surface.
Stræk huden godt sammen ved at bevæge din tommeltot og fingre i modsat retning, så der dannes et cirka 5 cm bredt område.
Stretch skin firmly by moving your thumb and fingers in the opposite direction, creating an area about 2 inches (5 centimetres) wide.
Stræk huden på de
Stretch the skin on
Stræk huden på de alternative injektionssteder.
Stretch the skin on alternate injection sites
Strækketeknik
Stretch technique
Strækmetoden
Stretch method
Strækmærker
Stretch marks
Strækmærker, blå mærker, akne-lignende udslæt, voldsom hårvækst i ansigtet, langsom sårheling
Stretch marks, bruising, acne-like rash, excessive growth of facial hair, slow wound healing.
Strømfrekvens (50/60 Hz) magnetfelt IEC 61000-4-8
Power frequency (50/60 Hz) magnetic field IEC 61000-4-8
Strømmen af ladede partikler ind og ud af muskelcellerne frembringer en kraftig elektrisk aktivitet, som fører til atrieflimren og hurtig hjertefrekvens.
The flow of charged particles in and out of the muscle cells produces the excessive electrical activity that leads to atrial fibrillation and rapid heart rate.
Studie
Stud y
studie (2004)
Study (2004)
Studie (alders- interval)
Study (Age range)
Studie 02507 var et randomiseret, dobbeltblindet, placebokontrolleret, multicenter klinisk studie med 40 patienter med GD1.
Study 02507 was a randomized, double-blind, placebo-controlled, multicenter clinical study in 40 patients with GD1.
Studie 034 var et 12-måneders, åbent sikkerhedsstudie med 40 patienter i alderen 2 år og opefter, som var blevet behandlet med imiglucerase i doser fra 15 til 60 enheder/kg i minimum 30 måneder i træk.
Study 034 was a 12-month, open-label safety study in 40 patients aged 2 years and older who had been receiving treatment with imiglucerase at doses ranging from 15 to 60 Units/kg for a minimum of 30 consecutive months.
Studie 1 brystcancer
Study 1 breast cancer
Studie 1 evaluerede 549 patienter med CF i alderen 12 år og ældre (gennemsnitsalder 25,1 år) med procent projiceret FEV1 (ppFEV1) ved screening fra 40-90 (gennemsnitlig ppFEV1 60,7 ved baseline [interval: 31,1 til 94,0]).
Trial 1 evaluated 549 patients with CF who were aged 12 years and older (mean age 25.1 years) with percent predicted FEV1 (ppFEV1) at screening between 40-90 (mean ppFEV1 60.7 at baseline [range:
Studie 1 og 2: Fase 3-studier med nyretransplantatrecipienter
Study 1 and 2: Phase 3 studies in renal transplant recipients
Studie 1 tilvejebragte de pivotale data for Empliciti i kombination med lenalidomid og dexamethason.
Study 1 provided the pivotal data for the indication for Empliciti in combination with lenalidomide and dexamethasone.
Studie 1 var dobbeltblindt og placebo- kontrolleret.
Study 1 was double-blind placebo controlled.
Studie 1*
Figure 1.
Studie 1, som er et fase 2 studie med patienter med aktiv, men klinisk stabil plaque psoriasis omfattende ≥ 10 % af kroppens overfladeareal.
Study 1 was a Phase 2 study in patients with active, but clinically stable, plaque psoriasis involving
Studie 106 og studie 107
Study 106 and Study 107
Studie 108 (ADVANCE)
Study 108 (ADVANCE)
Studie 110 var et randomiseret, dobbeltblindt, placebokontrolleret fase 2-studie, som blev udført hos patienter, der var co-inficeret med kronisk hepatitis C af genotype 1 og hiv, og som var behandlingsnaive for hepatitis C. Enten fik disse patienter ikke antiretroviral behandling (CD4- celletal ≥ 500 celler/mm3), eller de havde stabil, kontrolleret hiv (hiv-RNA < 50 kopier/ml, CD4- celletal ≥ 300 celler/mm3), som blev behandlet med efavirenz eller atazanavir/ritonavir i kombination med tenofovirdisoproxilfumarat og emtricitabin eller lamivudin.
Study 110 was a phase II randomised, double-blind, placebo-controlled study conducted in patients with chronic genotype 1 HCV/HIV co-infection who were treatment-naïve for hepatitis C. Patients were either not on antiretroviral therapy (CD4 count ≥ 500 cells/mm3), or had stable controlled HIV (HIV RNA < 50 copies/ml, CD4 count ≥ 300 cells/mm3) being treated with efavirenz or atazanavir/ritonavir in combination with tenofovir disoproxil fumarate and emtricitabine or lamivudine.
Studie 111 (ILLUMINATE)
Study 111 (ILLUMINATE)
Studie 1: Nyrer fra levende donorer og nyrer efter standardkriterier fra afdøde donorer
Study 1: living and standard criteria deceased donors
Studie 1: Recipienter til nyrer fra levende donorer og til nyrer efter standardkriterier fra afdøde donorer
Study 1: Recipients of Living Donor and Standard Criteria Deceased Donor Kidneys
Studie 2
2 x/week dosing
Studie 2 evaluerede 52 patienter, som var i alderen 6 til 11 år ved screening.
Study 2 evaluated 52 patients who were 6 to 11 years of age at screening; mean (SD) body weight was
Studie 2 vurderede effekten og sikkerheden af Xolair i en population med 312 svære allergiske Studie 2 vurderede effekten og sikkerheden af Xolair i en population med 312 svære allergiske astmatikere, som tilsvarede populationen i studie 1.
Study 2 assessed the efficacy and safety of Xolair in a population of 312 severe allergic asthmatics which matched the population in study 1.
Studie 2**
Study 1
Studie 2- data blev opnået fra CFQ-R for børn fra 6 til 11 år. d Hazard ratio for tid til første lungeforværring e Hos personer under 20 år (CDC vækstkurver)
Hazard ratio for time to first pulmonary exacerbation e In subjects under 20 years of age (CDC growth charts)
Studie 205 (n=396, n=303)
Study 205 (n=396; n=303)
Studie 206207-010
Study 206207-010
Studie 206207-011
Study 206207-011
Studie 2301: Vildagliptin 50 mg to gange daglig (N=90)
Study 2301: Vildagliptin 50 mg twice daily (N=90)
Studie 2384: Vildagliptin 50 mg to gange daglig (N=79)
Study 2384: Vildagliptin 50 mg twice daily (N=79)
Studie 2: Recipienter til donornyrer efter extended criteria
Study 2: Recipients of Extended Criteria Donor Kidneys
Studie 3 (del A) var et 16-ugers 4:1 randomiseret, dobbeltblindet, placebokontrolleret fase 2-studie med parallelle grupper af ivacaftor (150 mg hver 12. time) hos 140 patienter i alderen 12 år og derover med CF, som var homozygote for F508del-mutationen i CFTR-genet, og som havde FEV1 ≥40 % af forventet værdi.
Study 3 (part A) was a 16-week, 4:1 randomised, double-blind, placebo-controlled, parallel-group Phase 2 study of ivacaftor (150 mg every 12 hours) in 140 patients with CF age 12 years and older who were homozygous for the F508del mutation in the CFTR gene and who had FEV1 ≥40% predicted.
Studie 3 (fase 2-studie CAMMS223) evaluerede LEMTRADAs sikkerhed og virkning hos patienter med RRMS i mere end 5 år.
Study 3 (phase 2 study CAMMS223) evaluated the safety and efficacy of LEMTRADA in patients with RRMS over the course of 5 years.
Studie 3 er et fase III multicenter-rollover studie med parallelle grupper hos patienter med CF, der omfatter patienter fra studie 1 og studie 2.
Trial 3 is a Phase 3, parallel-group, multicentre, rollover study in patients with CF that includes patients from Trial 1 and Trial 2.
Studie 3 var et enkelt-arm studie med 30 patienter med recidiverende eller refraktær lavgrads, follikulær eller transformeret B-celle NHL, som havde mild trombocytopeni (blodpladetal 100.000 til 149.000 eller/mm3).
Study 3 was a single arm study of 30 patients with relapsed or refractory low-grade, follicular, or transformed B-cell NHL who had mild thrombocytopenia (platelet count 100,000 to 149,000 cells/mm3).
Studie 301 (n=305, n=256)
Study 301 (n=305; n=256)
Studie 301 indrullerede patienter, som tidligere havde fået docetaxel.
Study 301 enrolled patients who had received prior docetaxel.
Studie 301 – Samlet overlevelse (ITT-population)
Study 301 - Overall Survival (ITT Population)
Studie 302 indrullerede docetaxel-naive patienter, mens studie 301 indrullerede patienter, der tidligere havde fået docetaxel.
Study 302 enrolled docetaxel naïve patients; whereas, study 301 enrolled patients who had received prior docetaxel.
Studie 302 inkluderede ikke patienter med levermetastaser, og patienter med baseline-ALAT og -ASAT ≥2,5x ULN blev ekskluderet.
In the 302 trial, patients with liver metastases were not eligible and patients with baseline ALT and AST ≥ 2.5 x ULN were excluded.
Studie 309 - progressionsfri overlevelse i liposarkom-undergruppen
Study 309 – Progression Free Survival in the Liposarcoma Subgroup
Studie 309 Leiomyosarkom- undergruppe
Study 309 Leiomyosarcoma Subgroup
Studie 3: studie hos patienter med CF med F508del-mutation i CFTR-genet
Study 3: study in patients with CF with the F508del mutation in the CFTR gene
Studie 4: open-label-forlængelsesstudie
Study 4: open-label extension study
Studie 5 var et fase 3, todelt, randomiseret, dobbeltblindet, placebokontrolleret overkrydsningsstudie (del 1), efterfulgt af en 16-ugers open-label forlængelsesperiode (del 2), til at evaluere ivacaftors virkning og sikkerhed hos CF-patienter i alderen 6 år og derover, som har en non-G551D gating- mutation i CFTR-genet (G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P eller G1349D).
Study 5 was a Phase 3, two-part, randomised, double-blind, placebo-controlled, crossover study (part 1) followed by a 16-week open-label extension period (part 2) to evaluate the efficacy and safety of ivacaftor in patients with CF aged 6 years and older who have a non-G551D gating mutation in the CFTR gene (G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P or G1349D).
Studie 5615 var et ikke-sammenlignende multicenterstudie, som blev udført for at vurdere de farmakokinetiske egenskaber, sikkerheden og tolerabiliteten af posaconazol tabletten.
Study 5615 was a non-comparative multi-center study performed to evaluate the pharmacokinetic properties, safety, and tolerability of posaconazole tablet.
Studie 5: studie hos patienter med CF med non-G551D gating-mutationer
Study 5: study in patients with CF with non-G551D gating mutations
Studie 6: studie med patienter med CF i med en R117H-mutation i CFTR-genet
Study 6: study in patients with CF with an R117H mutation in the CFTR gene
Studie 7 var et placebokontrolleret studie, som inkluderede en specifik undergruppe (n=235) af patienter, som defineret i nuværende indikation, der blev behandlet med højdosis- inhalationskortikosteroid (500 μg/dag fluticason eller tilsvarende) samt langtidsvirkende beta- agonist.
Study 7 was a placebo-controlled trial which included a specific subgroup (n=235) of patients as defined in the present indication, who were treated with high-dose inhaled corticosteroids (≥500 µg/day fluticasone equivalent) plus long-acting beta agonist.
Studie A var et fase 1-studie, som omfattede en dosiseskaleringsfase og en forøgelsesfase ved den anbefalede dosis på 750 mg.
Study A was a phase 1 study which included a dose-escalation phase and an expansion phase, at the recommended dose of 750 mg.
Studie A1481262 var et enkeltcenter, enkeltdosis, open-label forsøg for at fastslå sikkerhed, tolerabilitet og farmakokinetik af en enkelt intravenøst administreret dosis sildenafil (10 mg) givet som en bolus-injektion til patienter med pulmonal arteriel hypertension, der allerede var i stabil behandling med oralt administreret Revatio 20 mg 3 gange dagligt.
Study A1481262 was a single centre, single dose, open label study to assess the safety, tolerability and pharmacokinetics of a single intravenous dose of sildenafil (10 mg) administered as a bolus injection to patients with Pulmonary Arterial Hypertension (PAH) who were already receiving and stable on oral Revatio 20 mg three times per day.
Studie A1481262 var et enkeltcenter, enkeltdosis, open-label studie for at fastslå sikkerhed, tolerabilitet og farmakokinetik af en enkelt intravenøst administreret dosis af sildenafil (10 mg) givet som en bolus-injektion til patienter med pulmonal arteriel hypertension, der allerede var i stabil behandling med oralt administreret Revatio 20 mg 3 gange dagligt.
Study A1481262 was a single centre, single dose, open label study to assess the safety, tolerability and pharmacokinetics of a single intravenous dose of sildenafil (10 mg) administered as a bolus injection to patients with PAH who were already receiving and stable on oral Revatio 20 mg TID.
Studie AI266922 var et ikke-blindet studie til evaluering af SUSTIVAs farmakokinetik, sikkerhed, tolerabilitet og antivirale aktivitet i kombination med didanosin og emtricitabin hos antiretroviral- naive og -erfarne pædiatriske patienter.
Study AI266922 was an open-label study to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of SUSTIVA in combination with didanosine and emtricitabine in antiretroviral-naive and -experienced paediatric patients.
Studie AI455-099 var et 48-ugers, randomiseret, dobbeltblindt studie med Zerit (40 mg, 2 gange daglig) i kombination med lamivudin (150 mg, 2 gange daglig) plus efavirenz (600 mg, 1 gang daglig) til 391 ikke tidligere behandlede patienter med et gennemsnitligt CD4-tal på 272 celler/mm3 (61 til 1215 celler/mm3) og et gennemsnitligt plasma HIV-1 RNA på 4,80 log10 kopier/ml (2,6 til 5,9 log 10 kopier/ml) ved baseline.
Study AI455-099 was a 48-week, randomised, double-blind study with Zerit (40 mg twice daily), in combination with lamivudine (150 mg twice daily) plus efavirenz (600 mg once daily), in 391 treatment-naive patients, with a median CD4 cell count of 272 cells/mm3 (range 61 to 1,215 cells/mm3) and a median plasma HIV-1 RNA of 4.80 log10 copies/ml (range 2.6 to 5.9 log 10 copies/ml) at baseline.
Studie AI455-099 var et 48-ugers, randomiseret, dobbeltblindt studie med Zerit (40 mg, 2 gange daglig) i kombination med lamivudin (150 mg, 2 gange daglig) plus efavirenz (600 mg, 1 gang daglig) til 391 ikke tidligere behandlede patienter med et gennemsnitligt CD4-tal på 272 celler/mm3 (61 til 1215 celler/mm3) og et gennemsnitligt plasma HIV-1 RNA på 4,80 log10 kopier/ml (2,6 til 5,9 log 10 kopier/ml) ved baseline.
Study AI455-099 was a 48-week, randomised, double-blind study withZerit (40 mg twice daily), in combination with lamivudine (150 mg twice daily) plus efavirenz (600 mg once daily), in 391 treatment-naive patients, with a median CD4 cell count of 272 cells/mm3 (range 61 to 1,215 cells/mm3) and a median plasma HIV-1 RNA of 4.80 log10 copies/ml (range 2.6 to 5.9 log 10 copies/ml) at baseline.
Studie AMD3100-3101 inkluderede 62 patienter (10 i gruppen på Mozobil + G-CSF og 52 i gruppen på placebo + G-CSF), som ikke kunne mobilisere tilstrækkeligt antal CD34+ celler og dermed ikke gennemgå transplantation, i en åben rescue-procedure med Mozobil og G-CSF.
In study AMD3100-3101, 62 patients (10 in the Mozobil + G-CSF group and 52 in the placebo + G- CSF group), who could not mobilise sufficient numbers of CD34+ cells and thus could not proceed to transplantation, entered into an open-label Rescue procedure with Mozobil and G-CSF.
Studie AMD3100-3101 – procentdel patienter med non-Hodgkins lymfom, der opnåede ≥ 5 x 106 CD34+ celler/kg efter et antal aferesedage
Study AMD3100-3101 – Proportion of patients who achieved ≥ 5 x 106 CD34+ cells/kg by apheresis day in non-Hodgkin’s lymphoma patients
Studie AMD3100-3102 – procentdel patienter med multipelt myelom, der opnåede ≥ 6 x 106 CD34+ celler/kg efter et antal aferesedage
Study AMD3100-3102 – Proportion of patients who achieved ≥ 6 x 106 CD34+ cells/kg by apheresis day in multiple myeloma patients
Studie APV3002 er en randomiseret, åben undersøgelse med 649 antiretroviral-behandlingsnaive patienter med fremskreden hiv-sygdom, hvor fosamprenavir/ritonavir (1400 mg/200 mg én gang daglig n=322) blev sammenlignet med nelfinavir (1250 mg to gange daglig, n=327), i begge tilfælde kombineret med lamivudin (150 mg to gange daglig) og abacavir (300 mg to gange daglig).
Study APV30002 is a randomised, open-label trial of 649 antiretroviral treatment naïve patients with advanced HIV-disease, investigating fosamprenavir/ritonavir (1400 mg/200 mg QD n=322) compared to nelfinavir (1250 mg BID n=327), each in combination with lamivudine (150 mg twice daily) and abacavir (300 mg twice daily).
Studie AVF3694g (capecitabin)
Study AVF3694g (capecitabine)
Studie B involverede 140 patienter, der tidligere var blevet behandlet med 1-3 cytotoksiske kemoterapilinjer efterfulgt af behandling med crizotinib, og som var progredieret på crizotinib.
Study B involved 140 patients who had been previously treated with 1-3 lines of cytotoxic chemotherapy followed by treatment with crizotinib, and who had then progressed on crizotinib.
Studie B var et fase 2-studie, der evaluerede effekt og sikkerhed ved 750 mg ceritinib hos patienter med lokalt fremskreden eller metastatisk ALK-positiv NSCLC.
Study B was a phase 2 study to evaluate the efficacy and safety of 750 mg ceritinib in patients with locally advanced or metastatic ALK-positive NSCLC.
Studie BO16348 var designet til at sammenligne 1 og 2-års Herceptin-behandling hver 3. uge versus observation hos patienter med HER2-positiv tidlig brystkræft efter operation, standard- kemoterapi og strålebehandling (hvis indiceret).
Study BO16348 was designed to compare one and two years of three-weekly Herceptin treatment versus observation in patients with HER2 positive EBC following surgery, established chemotherapy and radiotherapy (if applicable).
Studie C211 var et randomiseret, åbent fase 3-studie, der omfattede behandlingsnaive patienter, som blev randomiseret til en af de to behandlingsgrupper: INCIVO 750 mg hver 8. time [T12(q8h)/PR] eller INCIVO 1.125 mg to gange dagligt [T12(b.i.d.)/PR] i kombination med pegyleret interferon- alfa-2a and ribavirin.
Study C211 was a randomised, open-label, Phase 3 study conducted in treatment-naïve patients who were randomised to one of two treatment groups: INCIVO 750 mg every 8 hours [T12(q8h)/PR] or INCIVO 1,125 mg twice daily [T12(b.i.d.)/PR] in combination with peginterferon alfa-2a and ribavirin.
Studie C2305, patienter som ikke tidligere havde fået medicinsk behandling
Study C2305, patients who had no prior medical treatment
Studie C2402, utilstrækkeligt kontrollerede patienter
Study C2402, inadequately controlled patients
Studie CV1810393
Overall population (n=306)
Studie CV181057: tillæg til insulin (+/-metformin)
Study CV181057: add-on to insulin
Studie D1680L00006 (n=257)  n=Randomiserede patienter
n=Randomized patients
Studie D2301 (FREEDOMS) var et 2-årigt, placebokontrolleret klinisk studie med 854 patienter, som blev behandlet med fingolimod (placebo: 418).
Study D2301 (FREEDOMS) was a 2- year placebo-controlled clinical study in 854 patients treated with fingolimod (placebo: 418).
Studie D2301 (FREEDOMS) var et 2-årigt, randomiseret, dobbeltblindet, placebokontrolleret fase III- studie hos 1.272 patienter (n=425 på 0,5 mg, 429 på 1,25 mg og 418 på placebo).
Study D2301 (FREEDOMS) was a 2-year randomised, double-blind, placebo-controlled Phase III study of 1,272 patients (n=425 on 0.5 mg, 429 on 1.25 mg, 418 on placebo).
Studie D2309 (FREEDOMS II) var et 2-årigt placebokontrolleret klinisk studie hos 728 patienter med multipel sklerose, der blev behandlet med fingolimod (placebo: 355).
Study D2309 (FREEDOMS II) was a 2-year placebo-controlled clinical study in 728 multiple sclerosis patients treated with fingolimod (placebo: 355).
Studie Dag 3* (n=57)
Study Day 3* (n=57)
Studie E2100 (paclitaxel)
Study E2100 (paclitaxel)